A new antibiotic has been launched for treating complicated skin and soft tissue infections in hospitals and community acquired pneumonia.
Ceftaroline (Zinforo) has been developed specifically to tackle difficult to treat infections including MRSA in complicated skin and soft tissue infections and pneumococcal infection in community acquired pneumonia.
It was launched in the UK this week by manufacturer AstraZeneca and will cost £375 for a pack of 10 vials.
David Livermore, professor of medical microbiology at the University of East Anglia, said: “Although the number of MRSA bacteraemias in England has reduced by over 80% since its peak in 2003, MRSA remains an important cause of infection and continues to pose a serious health threat.
“It is therefore encouraging to see new treatment options for patients, such as ceftaroline – which is effective against MRSA in complicated skin and soft tissue infections – becoming available.”